Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - 50 mins ago
I've covered these dividend winners before, but you're not too late to get on board.
European Stocks Rebound Amid M&A, Earnings Headlines
at The Street - 54 mins ago
European stocks rebound on Thursday amid mergers and acquisitions excitement.
Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...
Encouraging Results from Pfizer's Xeljanz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 5:20PM CDT
Pfizer Inc. (PFE) announced encouraging top-line results from two pivotal phase III studies from the OPT Program on Xeljanz.
Final Glance: Pharmaceuticals companies
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 23, 12:37PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Hedge Funds Love These 5 Health Care Stocks -- but Should You?
at The Street - Wed Apr 23, 11:58AM CDT
Here's a look at five health care stocks that funds have been adding in the most recent quarter.
Cubist Pharma Posts Weak Earnings on Soft Cubicin Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 10:30AM CDT
Cubist Pharma missed both on earnings and revenues.
Early Glance: Pharmaceuticals companies
AP - Wed Apr 23, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Stock Market News for April 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 9:06AM CDT
Benchmarks ended higher on Tuesday boosted by better-than-expected corporate results
Global T-Cell Leukemia Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 14 Drug Profiles
M2 - Wed Apr 23, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/943p82/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Mundipharma International Limited - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - CytImmune Sciences, Inc. - Applied Immune Technologies Ltd Drug Profiles - mogamulizumab - forodesine hydrochloride - lenalidomide - Anti-Tac(Fv)-PE38 Immunotoxin - PF-03084014 - BMS-906024 - PCI-34051 - SL-101 - Lenaldekar - CYT-91000 - NK-314 - Immunotoxins - TCRL Antibodies For HTLV-1 - L1AD3 For more information visit http://www.researchandmarkets.com/research/94...l_leukemia
Amgen's Q1 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:40AM CDT
Amgen's first quarter results were disappointing with most of the products recording a sequential decline in sales.
Celgene to Rise Like a Phoenix: Opinion
at The Street - Wed Apr 23, 5:21AM CDT
Celgene's share price offers both growth or value investors something to like.
Asia shares mixed on lackluster China data
By ELAINE KURTENBACH - AP - Tue Apr 22, 11:08PM CDT
TOKYO (AP) — Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector.
Valeant, Ackman make $45.6B Allergan bid
AP - Tue Apr 22, 7:43PM CDT
NEW YORK (AP) — Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.
Drugmakers Prod European Stocks To Post-Easter Rally
at Investor's Business Daily - Tue Apr 22, 5:36PM CDT
European exchanges were high scorers on the world map Tuesday, as investors returned with vigor from the four-day holiday. Germany's Frankfurt Exchange led the pack, with the DAX index vaulting 2% higher. In Italy, Milano's FTSE MIB punched up 1.5%....
A Doozy of a Pharma Rumor
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 22, 5:30PM CDT
The latest health care acquisition rumor is a doozy. According to multiple news outlets, Pfizer was in talks with AstraZeneca to acquire the company for over $100 billion, although the companies apparently broke off talks. Interestingly, this...
Most active New York Stock Exchange-traded stocks
AP - Tue Apr 22, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Billionaire Ken Fisher's Top Stock Picks
Nicole Seghetti, The Motley Fool - Motley Fool - Tue Apr 22, 3:08PM CDT
Money managers must disclose their stock holdings every quarter, giving investors like you and me a peek into their portfolios. Based on his firm's first-quarter 13F SEC filing, here are multibillion-dollar fund manager Ken Fisher's top three stock...